Front Cover: Druggability Assessment for Selected Serine Proteases in a Pharmaceutical Industry Setting (ChemMedChem 21/2020),ChemMedChem

当前位置： X-MOL 学术 › ChemMedChem › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Front Cover: Druggability Assessment for Selected Serine Proteases in a Pharmaceutical Industry Setting (ChemMedChem 21/2020)
ChemMedChem ( IF 3.6 ) Pub Date : 2020-10-22 , DOI: 10.1002/cmdc.202000798
Leon Wehrhan ₁ , Alexander Hillisch ₁ , Stefan Mundt ₁ , Adrian Tersteegen ₁ , Katharina Meier ₁

Affiliation

The Front Cover shows the backbone representation of a protein structural ensemble for the serine protease FXa with a reticle pointing at it. The potential of targeting a protein with a drug‐like molecule plays an important role in early drug discovery. In their study, the authors address the topic of target druggability assessment. They present key insights from high‐throughput screening (HTS) and protein structure‐based druggability assessments and illustrate that conformational variability matters. More information can be found in the Full Paper by Leon Wehrhan, Katharina Meier et al.

中文翻译：

封面：制药行业中某些丝氨酸蛋白酶的可药性评估（ChemMedChem 21/2020）

封面显示了丝氨酸蛋白酶FXa的蛋白质结构集合的主干表示，并带有标线片。用类药物分子靶向蛋白质的潜力在早期药物发现中起着重要作用。在他们的研究中，作者讨论了目标可药物性评估的主题。他们从高通量筛选（HTS）和基于蛋白质结构的可药物性评估中提供了重要见解，并说明构象变异性至关重要。有关更多信息，请参见Leon Kathrina Meier等人的Leon Wehrhan的论文全文。

更新日期：2020-11-06

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文本刊介绍/投稿指南11